ARTICLE | Product Development
Readouts showcase promise of Roche’s brainshuttle; plus mixed results from Lilly, Lexeo and Anavex
By Selina Koch, Executive Editor
November 6, 2024 10:54 PM UTC
The latest data from Roche’s Phase Ib/IIa study of trontinemab suggest the pharma’s brainshuttle technology is doing its job.
The brainshuttle-enabled anti-amyloid mAb, concentrates in the CNS via active transport, appears on track to achieve the goal of accelerating β-amyloid plaque clearance and simultaneously decreasing the drug class’ most troublesome safety risks, brain swelling and hemorrhage…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654093/alzheimer-s-roundup-clinical-progress-and-setbacks-at-ctad